PALI
NASDAQPalisade Bio Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.96-0.09 (-4.39%)
2026-04-142026-07-17
News · 26 weeks55-33%
2026-01-182026-07-12
Mix3190d
- Insider12(39%)
- SEC Filings9(29%)
- Other9(29%)
- Leadership1(3%)
Latest news
25 items- INSIDERDirector Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- PRPalisade Bio to Participate in the Leerink Partners Therapeutics ForumManagement to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts. Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical developmen
- INSIDERDirector Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERChief Medical Officer Jones Mitchell Lawrence converted options into 131,167 shares and sold $106,536 worth of shares (51,880 units at $2.05), increasing direct ownership by 539% to 94,009 units (SEC Form 4) to satisfy tax liability4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERCEO, CFO Finley John David exercised 335,300 shares at a strike of $0.00 and sold $303,343 worth of shares (146,798 units at $2.07), increasing direct ownership by 646% to 217,688 units (SEC Form 4) to cover withholding tax4 - PALISADE BIO, INC. (0001357459) (Issuer)
- SECSEC Form 144 filed by Palisade Bio Inc.144 - PALISADE BIO, INC. (0001357459) (Subject)
- INSIDERDirector Baltera Robert Jr. bought $59,400 worth of shares (30,000 units at $1.98), increasing direct ownership by 9% to 366,904 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- PRPalisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative ColitisASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027 IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio Denver, CO, June 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that the U.S. Food and
- INSIDERDirector Baltera Robert Jr. was granted 336,904 shares (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by new insider Baltera Robert Jr.3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Wei Binxian was granted 592,300 shares and converted options into 20,200 shares, increasing direct ownership by 71,637% to 613,355 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Williams Donald Allen converted options into 60,666 shares and was granted 1,498,900 shares, increasing direct ownership by 14,537% to 1,570,294 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Chuang Emil was granted 592,300 shares and converted options into 20,200 shares (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Zwick Jordan Michael was granted 336,904 shares (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zwick Jordan Michael3 - PALISADE BIO, INC. (0001357459) (Issuer)
- SECPalisade Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of DirectorsBoard strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the addition of Robert Baltera and Jordan Zwick to its Board of Directors. "We are pleased to welcome both Robert and Jordan to the Palisade Bio Board
- SECSEC Form S-8 filed by Palisade Bio Inc.S-8 - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences SymposiumPresentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced Mitchell Jones, MD, PhD, President and Chief Medical Officer, will present at the New York Academy of Sciences ("NYAS") symposium, Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis, taking place on June 9, 2026, in New York, NY.
- PRPalisade Bio to Participate in the Jefferies Global Healthcare ConferenceManagement presentation to take place on Thursday, June 4th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Jefferies Global Healthcare Conference, being held June 2-4, 2026, in New York, New York. The Company's presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM E
- SECSEC Form EFFECT filed by Palisade Bio Inc.EFFECT - PALISADE BIO, INC. (0001357459) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
- SECSEC Form SCHEDULE 13G filed by Palisade Bio Inc.SCHEDULE 13G - PALISADE BIO, INC. (0001357459) (Subject)
- SECSEC Form S-3 filed by Palisade Bio Inc.S-3 - PALISADE BIO, INC. (0001357459) (Filer)
PALI FAQ
6 questionsWhat does Palisade Bio Inc. do?
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad...Where does PALI stock trade?
Palisade Bio Inc. (PALI) is listed on NASDAQ.What sector and industry is PALI in?
Palisade Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about PALI?
Palisade Bio Inc. has had 7 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $700.00 price target on 2026-04-09. Recent price targets range from $500.00 to $2500.00.What companies are similar to PALI?
Notable peers in the same industry include GRPH (Graphite Bio Inc.), CABA (Cabaletta Bio Inc.), ACET (Adicet Bio Inc.), INMB (INmune Bio Inc.), TIL (Instil Bio Inc.). Compare PALI side-by-side with any of them on Quantisnow.How can I track PALI on Quantisnow?
Quantisnow aggregates Palisade Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PALI to receive live email and push alerts on every new disclosure.